Ovarian cancer: Prevention, detection, and treatment of the disease and its recurrence. Molecular mechanisms and personalized medicine meeting report

International Journal of Gynecological Cancer

Volumn 22, Issue 8, 2012, Pages

  Modugno, Francesmary ^a,b,c   Edwards, Robert P ^a,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Biomarkers; BRCA1 2; Cancer stem cells; Cancer vaccines; Clinical trials; Epidemiology; Etiology; Genomics; Individualized medicine; Metabalomics; Micro RNA; Nuclear receptors; Ovarian neoplasms; Patient reportable outcomes; Proteomics; Quality of life; Screening; Survival; Therapeutics

Indexed keywords

BIOLOGICAL MARKER; CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RECURRENCE; CANCER RESEARCH; CANCER STAGING; CANCER STEM CELL; CANCER SURGERY; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DOCTOR PATIENT RELATION; EARLY DIAGNOSIS; HEREDITY; HUMAN; OVARY CARCINOMA; PERSONALIZED MEDICINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SALPINGOOOPHORECTOMY;

BIOMEDICAL RESEARCH; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RESEARCH REPORT;

EID: 84867240781     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31826bd1f2     Document Type: Review

References (25)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Modugno F; Ovarian Cancer and High-Risk Women Symposium presenters. Ovarian cancer and high-risk womenVimplications for prevention, screening, and early detection. Gynecol Oncol. 2003;91:15-31.
3. Scully RE. Early de novo ovarian cancer and cancer developing in benign ovarian lesions. Int J Gynaecol Obstet. 1995;49:S9YS15.
4. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451-456.
5. Auersperg N. The origin of ovarian carcinomas: a unifying hypothesis. Int J Gynecol Pathol. 2011;30:12-21.
6. Giudice LC, Kao LC. Endometriosis. Lancet. 2004;364:1789-1799.
7. Titus-Ernstoff L, Rees JR, Terry KL, et al. Breast-feeding the last born child and risk of ovarian cancer. Cancer Causes Control. 2010;21:201-207.
8. Goode EL, Chenevix-Trench G, Song H, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet. 2010;42:874-879.
9. Ovarian cancer association ConsortiumPublications [homepage on the Internet]. June 11, 2012. Available at: http://ccge.medschl.cam.ac.uk/consortia/ ocac/pubs/pubs.html. July 10, 2012.
10. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK collaborative trial of ovarian cancer screening (UKCTOCS). Lancet Oncol. 2009;10:327-340.
11. Gross AL, Kurman RJ, Vang R, et al. Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics. J Oncol. 2010;2010:126295.
12. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161-169.
13. Rungruang B, Hood BL, Sun M, et al. Novel surgical approaches for sampling the ovarian surface epithelium and proximal fluid proteome. J Proteome Res. 2010;9:6071-6076.
14. Kim J, Coffey DM, Creighton CJ, et al. High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A. 2012;109:3921-3926.
15. Chambers SK. Role of CSF-1 in progression of epithelial ovarian cancer. Future Oncol. 2009;5:1429-1440.
16. Flint MS, Budiu RA, Teng PN, et al. Restraint stress and stress hormones significantly impact T lymphocyte migration and function through specific alterations of the actin cytoskeleton. Brain Behav Immun. 2011;25:1187-1196.
17. Wright CE, Bovbjerg DH, Montgomery GH, et al. Disrupted sleep the night before breast surgery is associated with increased postoperative pain. J Pain Symptom Manage. 2009;37:352-362.
18. Carey MS, Gotay C; Gynecologic Cancer InterGroup (GCIG). Patient-reported outcomes: clinical trials in ovarian cancer. Int J Gynecol Cancer. 2011;21:782-787.
19. Bodurka DC, von Gruenigen VE.Women's cancer survivorship: time to gear up! Gynecol Oncol. 2012;124:377-378.
20. Meirelles K, Benedict LA, Dombkowski D, et al. Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by mullerian inhibiting substance. Proc Natl Acad Sci U S A. 2012;109:2358-2363.
21. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102:18538-18543.
22. Muthuswamy R, Berk E, Fallert Junecko B, et al. NF-JB hyper-activation in tumor tissues allows tumor-selective reprogramming of chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res. 2012;72:3735-3743.
23. McNeil SE. Nanoparticle therapeutics: a personal perspective. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1:264-271.
24. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483:100-103.
25. Vaughan S, Coward JI, Bast RC Jr, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11:719-725.